Discover Our Peptide Solutions
At HealthLab, we harness the potential of peptides for research only. Our products are meticulously crafted, ensuring you receive top-notch support for your research journey.
Tirz Blog
At HealthLab, we harness the potential of peptides for research only. Our products are meticulously crafted, ensuring you receive top-notch support for your research journey.
N Engl J Med
. 2025 Jul 3;393(1):26-36. doi: 10.1056/NEJMoa2416394. Epub 2025 May 11.
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Louis J Aronne 1, Deborah Bade Horn 2, Carel W le Roux 3 4, Wayne Ho 5 6, Beverly L Falcon 7, Elisa Gomez Valderas 7, Sagar Das 7, Clare J Lee 7, Leonard C Glass 7, Cagri Senyucel 7, Julia P Dunn 7; SURMOUNT-5 Trial Investigators
Collaborators, Affiliations Expand
PMID: 40353578 DOI: 10.1056/NEJMoa2416394
Abstract
Background: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown.
Methods: In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. The primary end point was the percent change in weight from baseline to week 72. Key secondary end points included weight reductions of at least 10%, 15%, 20%, and 25% and a change in waist circumference from baseline to week 72.
Results: A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001). The least-squares mean change in waist circumference was -18.4 cm (95% CI, -19.6 to -17.2) with tirzepatide and -13.0 cm (95% CI, -14.3 to -11.7) with semaglutide (P<0.001). Participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%. The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation.
Conclusions: Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.).
Copyright © 2025 Massachusetts Medical Society.
Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP; SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025 Jul 3;393(1):26-36. doi: 10.1056/NEJMoa2416394. Epub 2025 May 11. PMID: 40353578.
Some research currently available on Tirzepatide coming to this blog soon. All products sold by http://www.healthlabpeptides.com are strictly intended for laboratory research purposes only.
Products are not intended for human or animal consumption, medical treatment, diagnosis, prevention, or cure of any condition. Products are not to be used as supplements, Bodybuilding for weight loss, Lean muscle gain, Fat loss workout plans, Weight loss transformation, Strength training and fat loss, Building muscle while losing weight, Nutrition for bodybuilding and weight loss, Calories burned in weightlifting, Workout plans for muscle and fat loss, and Supplement stack for weight loss and muscle gain, drugs, medical devices, cosmetics, food, or additives under any circumstance. Only qualified, licensed professionals are permitted to handle, store, and utilize these materials in controlled research environments.
Any misuse, alteration, or unauthorized application of products is strictly prohibited and may violate federal law, including the Federal Food, Drug, and Cosmetic Act. Healthlab Peptides makes NO health or wellness claims about any of these products on this website or any other product.
HealthLab Peptides wishes to clarify that it does not endorse, review, or moderate any posts on this blog. The content shared here is intended solely for informational purposes and aims to showcase research conducted on peptides. However, it is important to note that the accuracy and reliability of the information presented in each post may vary, as HealthLab Peptides does not verify the claims made by contributors. Additionally, HealthLab Peptides makes no health or wellness claims regarding any of the products featured on the website. Readers are encouraged to exercise their discretion and consult qualified professionals or trusted sources for guidance regarding peptides and their applications. The blog serves as a platform for discussion and exploration of scientific Research only topics and should not be considered an authoritative resource.
article: https://pmc.ncbi.nlm.nih.gov/articles/PMC12394919/